Imatinib for priority review by US FDA for GIST recurrence.

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

The US FDA has granted priority review for bortezomib [Velcade] for the treatment of patients with newly diagnosed multiple myeloma (MM).

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Prasugrel FDA approval decision: for whom is the timing out?

By  

Inpharma, Vol. 1, Iss. 1644, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

The prasugrel new drug application (NDA) is still under discussion with the US FDA

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

US FDA grants orphan drug designation for imisopasem manganese

By  

Inpharma, Vol. 1, Iss. 1629, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite